Ta’sirlangan ichakni davolash

Zamonaviy turmush tarzi, zararli mahsulotlar, yurib ketayotganda tamaddi qilish, stresslar, ortiqcha toliqishlik ichakka salbiy ta’sir qiladi.

Ichak kasalliklaridan eng tarqalganlaridan biri - ta’sirlangan ichak sindromidir. U axlat chiqarilishini buzilishi bilan birgalikda qorindagi og‘riq bilan namoyon bo‘ladi. Bu qabziyat, diyareya yoki ularning navbatlashishi bo‘lishi mumkin.

Ma’lumotnoma. Ta’sirlangan ichak sindromidan yer kurrasining taxminan 10% aholisi a’ziyat chekadi. Bunda kasallanish cho‘qqisi 25-40 yoshdagi katta mehnatga layoqatli aholiga to‘g‘ri keladi. Ayollarda TIS erkaklarga qaraganda 1,5-2 marta ko‘proq uchraydi.

Ta’sirlangan ichak sindromining aniq sabablari noaniqdir. Odatda, TIS kuchli stresslar yoki me’da-ichak infeksiyalaridan keyin rivojlanadi.

TIS - surunkali kasallik: zo‘riqish davrlari simptomlar kamroq bezovta qilishi vaqtidagi davrlar bilan navbatlashadi.

TIS simptomlari

TISning asosiy belgisi - qorinda vaqti-vaqti bilan (haftasiga bir marta va undan ko‘proq) yuzaga keluvchi og‘riq. U, odatda, ovqatlanishdan keyin yuzaga keladi va ich bo‘shalishidan keyin kamayadi yoki g‘oyib bo‘ladi. Ichning bo‘shalishi har xil ko‘rinishlarda sodir bo‘lishi mumkin: qabziyat yoki diareya. Axlat chiqarishning buzilishini ustunlikdagi turiga bog‘liq holda TISning uchta varianti ajratib ko‘rsatiladi:

• qabziyat bilan;
• diareya bilan;
• aralash variant, diareya qabziyat bilan navbatlashganda.

TIS qorinning dam bo‘lishi - shishganlikning noxush hissi bilan kuzatilishi mumkin. U ertalabki soatlarda kamroq ifoda etiladi, kun davomida o‘sib boradi va taom qabul qilinishidan keyin kuchayadi.

Ayollarda simptomlar hayz vaqtida kuchayishi mumkin.

TIS simptomlarining sabablari - a’zoda tuzilmaviy o‘zgarishlar (o‘sma, yara yoki striktura) emas, balki uning funksiyalarining buzilishi: ichakning motorikasini buzilishi va uning yuqori sezuvchanligi.

TIS bo‘lgan odamlarning deyarli yarmida motorikaning va sezuvchanlikning buzilishi me’daga ham ta’sir qiladi. Bunda, TIS simptomlariga ovqatlanishdan keyin me’da sohasidagi og‘irlik, ishtahaning pasayishi (me’daning sekinlashgan motorikasi belgisi) qo‘shiladi.

Me’da-ichak yo‘lining bir vaqtda bir nechta funksional kasalliklari mavjudligi "MIYning kesishuvchan funksional kasalliklari sindromi" nomini olgan.

Shunga o‘xshash simptomlar ko‘pchilik kasalliklarda, shu jumladan xavfli va hayotga tahdid soluvchi kasalliklarda ham yuzaga kelishi mumkin, shuning uchun shaxsiy tashxislash va o‘z-o‘zini davolash bilan shug‘ullanish emas, balki shifokorga murojaat qilish muhimdir.

TISni davolash

Baxtimizga, TIS mavjudligi og‘ir xastaliklar - yomon sifatli hosil bo‘lishlar, ichakning yallig‘lanish kasalliklari rivojlanishi xavfini oshirmaydi. Ammo, bunda, sindromning o‘zi salmoqli noqulayliklarni keltiradi va hayotning sifatiga ta’sir etadi. Zamonaviy davolash simptomlarni nazorat ostiga olishga imkon beradi.

Spazmolitiklar mana o‘n yildirki ta’sirlangan ichak sindromi simptomlarini nazorat qilish uchun asosiy vosita bo‘lib qolmoqda. Bunday preparatlar ichakdagi spazmlarni oladi, bu qorindagi og‘riqni va undagi noqulaylikni yengillashtirishga imkon beradi.

Spazmolitiklar quyidagicha bo‘lishi mumkin:

• Noselektiv. Bunday preparatlarga, masalan, ta’sir etuvchi moddasi drotaverin bo‘lgan dorilar kiradi. Noselektiv vositalar nafaqat me’da-ichak yo‘lining va safro chiqaruvchi yo‘llarning silliq muskulaturasiga, balki siydik-tanosil tizimning silliq muskulaturasiga va qon tomirlarga ham ta’sir qiladi. Bir tomondan, bu bosh og‘rig‘ini, zo‘riqqanlikni yengillashtirish uchun, va ayollarda hayz og‘riqlarini bartaraf qilish uchun mos keluvchi universal vositadir. Boshqa tomondan, qon tomirlarga ta’sir qilishi sababli drotaverin arterial bosimni pasaytirilishini chaqirishi mumkin.
• Selektiv. Ularga, xususan, trimebutin yoki MIY va safro chiqaruvchi yo‘llarga tanlab ta’sir etuvchi Trimedat^® kiritadi.

Trimedat^®da bir nechta xususiyatlar bor:

• Birinchidan, u nafaqat yo‘g‘on ichakning, balki me’da-ichak yo‘li va safro chiqaruvchi yo‘llarning ham motorikasini me’yorlashtiradi.
• Ikkinchidan, u buzilishlarning tusiga bog‘liq bo‘lmagan holda MIY motorikasini me’yorlashtiradi. Masalan spazmlarda Trimedat^® spazmolitik kabi ta’sir qiladi, balki shu vaqtning o‘zida sekinlashtirilgan motorikasini faollashtiradi, ya’ni, prokinetik kabi ishlaydi. Shunday qilib, kesishuvchanlik sindromida, ichakdagi spazmlar me’daning sekinlashgan motorikasi bilan uyg‘unlashgan vaqtda, Trimedat^®ning o‘zi ikkita: ichak uchun spazmolitik va me’da uchun prokinetik preparatlarni o‘rnini bosadi.
• Uchinchidan, Trimedat^® me’da-ichakning ko‘tarilgan sezuvchanligini me’yorlashtirishga qodirdir.

Natijada, Trimedat^® MIYning funksional kasalliklari simptomlarini keng doirasini: qorin sohasidagi og‘riq, ichni dam bo‘lishi hissi, me’dadagi og‘irlik, axlat chiqarishning buzilishini bartaraf qilishga yordam beradi.

Spazmolitik vositalar kurs bilan qo‘llaniladi, masalan, Trimedat^® 28 kundan qabul qilinadi. Bunday preparatlar bilan kurs davolanishi TIS simptomlaridan dam olishga imkon yaratadi, bundan tashqari, ba’zi tadqiqotlar ko‘rsatganidek, kurs qabul qilinishi kelajakda ancha uzoq muddatli remissiyaga erishish imkonini oshiradi.

TISda spazmolitiklarga qo‘shimcha sifatida boshqa dorilar ham buyurilishi mumkin. Davolash sxemasini faqat shifokor tanlay oladi. Sog‘liqqa shikoyatlar yuzaga kelishida shifokorga murojaat qiling.

Qorningizga yordam berish uchun, birinchi yengillashishda davolashni to‘xtatib qo‘ymang. Sabr qiling va shifokor tomonidan tayinlangan dorilarni qabul qilish kursiga rioya qiling.

Adabiyotlar ro‘yxati

1. How does the intestine work?/ InformedHealth.org, April 14, 2011; update: May 17, 2018. https://www.ncbi.nlm.nih.gov/books/NBK279303/
2. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review/ Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG, Gastroenterology, 2012 Jan; 142(1):46-54.e42; quiz e30.https://pubmed.ncbi.nlm.nih.gov/22001864/
3. Abdominal Pain/ Roger Sherman, Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. https://www.ncbi.nlm.nih.gov/books/NBK412/
4. Diarrhea/ National Institute of Diabetes and Digestive and Kidney Diseases.https://www.niddk.nih.gov/health-information/digestive-diseases/diarrhea
5. Constipation/ National Institute of Diabetes and Digestive and Kidney Diseases.https://www.niddk.nih.gov/health-information/digestive-diseases/constipation
6. Gas and gas pains/ Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/gas-and-gas-pains/symptoms-causes/syc-20372709
7. Gas and Bloating/ William L. Hasler, Gastroenterology and Hepatol0gy, 2006 Sep; 2(9): 654–662. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350578/
8. Colitis/ Samy A. Azer, Yan Sun. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK541037/
9. Ulcerative Colitis/ National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis
10. Irritable Bowel Syndrome (IBS)/ National Institute of Diabetes and Digestive and Kidney Diseases.https://www.niddk.nih.gov/health-information/digestive-diseases/irritable-bowel-syndrome
11. Microbiome and Gut Dysbiosis/ José E Belizário, Joel Faintuch, Experientia Supplementum, 2018; 109:459-476.https://pubmed.ncbi.nlm.nih.gov/30535609/
12. Trimebutine: a state-of-the-art review/ Beatrice Salvioli, Minerva Gastroenterologica and Dietologica, 2019 Sep; 65(3):229-238.https://pubmed.ncbi.nlm.nih.gov/31617696/
13. Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome/ Suma Magge, Anthony Lembo, Gastroenterology and Hepatology.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966170/
14. Consumption of spicy foods and the prevalence of irritable bowel syndrome/ Ahmad Esmaillzadeh, Ammar Hassanzadeh Keshteli, Maryam Hajishafiee etc., World Journal of Gastroenterology, v.19(38); 2013 Oct.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801318/
15. The Impact of Alcohol in Inflammatory Bowel Diseases/ Bradley A White, Guilherme Piovezani Ramos, Sunanda Kane, Inflammatory Bowel Diseases, 2021 May 14; izab 089.https://pubmed.ncbi.nlm.nih.gov/33988227/
16. Dietary behaviors in relation to prevalence of irritable bowel syndrome in adolescent girls/
    
    Sayyed Saeid Khayyatzadeh, Seyyed Mohammad Reza Kazemi-Bajestani, Seyed Jamal Mirmousavi etc., Journal of Gastroenterology and Hepatology, 2018 Feb; 33(2):404-410. https://pubmed.ncbi.nlm.nih.gov/28770579/
17. Inflammatory Bowel Disease and Physical Activity: A Study on the Impact of Diagnosis on the Level of Exercise Amongst Patients With IBD/ K Gatt, J Schembri, K H Katsanos, D Christodoulou etc., Journal of Crohn’s and Colitis, 2019 May 27; 13(6):686-692. https://pubmed.ncbi.nlm.nih.gov/30561568/
18. Effects of regular physical activity on defecation pattern in middle-aged patients complaining of chronic constipation/ Anneke M De Schryver, Yolande C Keulemans, Harry P Peters etc., Scandinavian Journal of Gastroenterology, 2005 Apr; 40(4):422-9. https://pubmed.ncbi.nlm.nih.gov/16028436/
19. Impact of psychological stress on irritable bowel syndrome/ Hong-Yan Qin, Chung-Wah Cheng, Xu-Dong Tang, Zhao-Xiang Bian, World Journal of Gastroenterology, 2014 Oct 21; 20(39): 14126–14131. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202343/
20. The challenge of patient adherence/ Leslie R Martin, Summer L Williams, Kelly B Haskard, M Robin DiMatteo, Therapeutics and Clinical Risk Management, 2005 Sep; 1(3): 189-199. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661624/
21. ИМП Тримедат^® ЛП-002527.
22. ИМП Тримедат^® форте ЛП-004600.
23. ИМП Тримедат^® ЛП-006704.